A fourth dimension in decision making in hepatology

Hepatology Research

Volumn 40, Issue 12, 2010, Pages 1143-1154

  Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Breath test; Cirrhosis; Liver fibrosis; Liver function

Indexed keywords

4 ACETANISIDINE; ALANINE AMINOTRANSFERASE;

ANTIVIRAL THERAPY; BARIATRIC SURGERY; BREATH ANALYSIS; CHRONIC LIVER DISEASE; DECISION MAKING; HEPATITIS B; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TOXIC HEPATITIS;

EID: 78649854046     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00737.x     Document Type: Review

References (105)

1. Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions. Liver 1982; 2: 369-75.
2. Cherry DJ, McLellan GH. Bromsulphthalein retention test and gamma-glutamyl transpeptidase activity in the investigation of liver disease. Pathology 1978; 10: 145-8.
3. Ercolani G, Grazi GL, Calliva R et al. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery 2000; 127: 464-71.
4. Faybik P, Hetz H. Plasma disappearance rate of indocyanine green in liver dysfunction. Transplant Proc 2006; 38: 801-2.
5. Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection. Hepatol Res 2009; 39: 107-16.
6. Stintzing S, Schmitt C, Ocker M et al. Liver function under interferon/ribavirin therapy of chronic hepatitis C. Hepatogastroenterology 2009; 56: 462-5.
7. Addario L, Scaglione G, Tritto G et al. Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study. Eur J Gastroenterol Hepatol 2006; 18: 713-20.
8. Botta F, Giannini E, Romagnoli P et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52: 134-9.
9. Arrigoni A, Gindro T, Aimo G et al. Monoethylglicinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994; 20: 383-7.
10. Testa R, Valente U, Risso D et al. Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? Eur J Gastroenterol Hepatol 1999; 11: 559-63.
11. Schneider A, Caspary WF, Saich R et al. 13C-methacetin breath test shortened: 2-point-measurements after 15 minutes reliably indicate the presence of liver cirrhosis. J Clin Gastroenterol 2007; 41: 33-7.
12. Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291: 1384-8.
13. Ilan Y. Review article: the assessment of liver function using breath tests. Aliment Pharmacol Ther 2007; 26: 1293-302.
14. Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006; 63: 2340-8.
15. Liu L, Pang KS. An integrated approach to model hepatic drug clearance. Eur J Pharm Sci 2006; 29: 215-30.
16. Barstow L, Small RE. Liver function assessment by drug metabolism. Pharmacotherapy 1990; 10: 280-8.
17. Stehr A, Ploner F, Traeger K et al. Plasma disappearance of indocyanine green: a marker for excretory liver function? Intensive Care Med 2005; 31: 1719-22.
18. Hsieh CB, Yu CY, Tzao C et al. Prediction of the risk of hepatic failure in patients with portal vein invasion hepatoma after hepatic resection. Eur J Surg Oncol 2006; 32: 72-6.
19. Yan W, Xiong P, Liu Z, Huang G. Results of L-[1-13C]phenylalanine breath test with air isotope ratio mass spectrometry can reflect the activity of phenylalanine hydroxylase in cirrhotic rat liver. Rapid Commun Mass Spectrom 2006; 20: 602-8.
20. Koeda N, Iwai M, Kato A, Suzuki K. Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis. Aliment Pharmacol Ther 2005; 21: 851-9.
21. Perri F, Marras RM, Ricciardi R, Quitadamo M, Andriulli A. 13C-breath tests in hepatology (cytosolic liver function). Eur Rev Med Pharmacol Sci 2004; 8: 47-9.
22. Park GJ, Katelaris PH, Jones DB et al. The C-caffeine breath test distinguishes significant fibrosis in chronic hepatitis B and reflects response to lamivudine therapy. Aliment Pharmacol Ther 2005; 22: 395-403.
23. Milazzo L, Piazza M, Sangaletti O et al. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2005; 55: 84-9.
24. Klatt S, Taut C, Mayer D, Adler G, Beckh K. Evaluation of the 13C-methacetin breath test for quantitative liver function testing. Z Gastroenterol 1997; 35: 609-14.
25. Adamek RJ, Goetze O, Boedeker C, Pfaffenbach B, Luypaerts A, Geypens B. 13C-methacetin breath test: isotope-selective nondispersive infrared spectrometry in comparison to isotope ratio mass spectrometry in volunteers and patients with liver cirrhosis. Z Gastroenterol 1999; 37: 1139-43.
26. Matsumoto K, Suehiro M, Iio M et al. [13C]methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987; 32: 344-8.
27. Braden B, Faust D, Sarrazin U et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2005; 21: 179-85.
28. Braden B, Lembcke B, Kuker W, Caspary WF. (13)C-breath tests: current state of the art and future directions. Dig Liver Dis 2007; 39: 795-805.
29. Israeli E, Ilan Y, Meir SB, Buenavida C, Goldin E. A novel 13C-urea breath test device for the diagnosis of Helicobacter pylori infection: continuous online measurements allow for faster test results with high accuracy. J Clin Gastroenterol 2003; 37: 139-41.
30. Lysy J, Israeli E, Strauss-Liviatan N, Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients. Neurogastroenterol Motil 2006; 18: 433-40.
31. Massard J, Ratziu V, Thabut D et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24.
32. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56.
33. Albanis E, Friedman SL. Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. Clin Liver Dis 2006; 10: 821-33.
34. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
35. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26: 122S-7S.
36. Perrillo RP. The role of liver biopsy in hepatitis C. Hepatology 1997; 26: 57S-61S.
37. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999; 19 (Suppl 1): 35-47.
38. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26: 133S-6S.
39. Kelleher TB, Afdhal N. Assessment of liver fibrosis in co-infected patients. J Hepatol 2006; 44: S126-31.
40. Olga OZ, Nikolai DY. Invasive and non-invasive monitoring of hepatitis C virus-induced liver fibrosis: alternatives or complements? Curr Pharm Biotechnol 2003; 4: 195-209.
41. Goetze O, Selzner N, Fruehauf H, Fried M, Gerlach T, Mullhaupt B. 13C-methacetin breath test as a quantitative liver function test in patients with chronic hepatitis C infection: continuous automatic molecular correlation spectroscopy compared to isotopic ratio mass spectrometry. Aliment Pharmacol Ther 2007; 26: 305-11.
42. Portincasa P, Grattagliano I, Lauterburg BH, Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006; 111: 135-43.
43. Festi D, Capodicasa S, Sandri L et al. Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. World J Gastroenterol 2005; 11: 142-8.
44. Lalazar G, Pappo O, Hershcovici T et al. A continuous (13)C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat 2008; 15: 716-28.
45. Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol 2007; 46: 751-5.
46. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179-84.
47. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005; 2: 82.
48. Strader DB. Understudied populations with hepatitis C. Hepatology 2002; 36: S226-36.
49. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009; 49: S129-37.
50. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-55.
51. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14 (Suppl 1): 6-10.
52. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis 2007; 27 (Suppl 1): 3-8.
53. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36: S114-20.
54. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 49: S96-S102.
55. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009; 49: S166-73.
56. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-78.
57. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
58. Belongia EA, Costa J, Gareen IF et al. NIH consensus development statement on management of hepatitis B. NIH Consens State Sci Statements 2008; 25: 1-29.
59. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.
60. Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009; 50: 412-20.
61. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-22.
62. Shiffman ML, Luketic VA, Sanyal AJ, Thompson EB. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease. Ther Drug Monit 1996; 18: 372-7.
63. Furrer K, Deoliveira ML, Graf R, Clavien PA. Improving outcome in patients undergoing liver surgery. Liver Int 2007; 27: 26-39.
64. Sugimoto H, Okochi O, Hirota M et al. Early detection of liver failure after hepatectomy by indocyanine green elimination rate measured by pulse dye-densitometry. J Hepatobiliary Pancreat Surg 2006; 13: 543-8.
65. Chung H, Kudo M, Haji S et al. A proposal of the modified liver damage classification for hepatocellular carcinoma. Hepatol Res 2006; 34: 124-9.
66. Sakka SG, Van Hout N. Relation between indocyanine green (ICG) plasma disappearance rate and ICG blood clearance in critically ill patients. Intensive Care Med 2006; 32: 766-9.
67. Ohwada S, Kawate S, Hamada K et al. Perioperative real-time monitoring of indocyanine green clearance by pulse spectrophotometry predicts remnant liver functional reserve in resection of hepatocellular carcinoma. Br J Surg 2006; 93: 339-46.
68. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am 2004; 84: 355-73.
69. Shirin H, Aeed H, Shalev T et al. Utility of a 13C-methacetin breath test in evaluating hepatic injury in rats. J Gastroenterol Hepatol 2008; 23: 1762-8.
70. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
71. Cholongitas E, Senzolo M, Patch D, Shaw S, Hui C, Burroughs AK. Review article: scoring systems for assessing prognosis in critically ill adult cirrhotics. Aliment Pharmacol Ther 2006; 24: 453-64.
72. Blei AT. Selection for acute liver failure: have we got it right? Liver Transpl 2005; 11: S30-4.
73. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
74. Mullin EJ, Metcalfe MS, Maddern GJ. How much liver resection is too much? Am J Surg 2005; 190: 87-97.
75. Freeman RB Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008; 47: 1052-7.
76. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28: 110-22.
77. Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008; 28: 606-13.
78. Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006; 26: 211-20.
79. Samuel D. MELD-Na as a prognostic score for cirrhotic patients: hyponatremia and ascites are back in the game. J Hepatol 2009; 50: 836-8.
80. Wong VW, Chim AM, Wong GL, Sung JJ, Chan HL. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl 2007; 13: 1228-35.
81. Sumskiene J, Kupcinskas L, Pundzius J, Sumskas L. Prognostic factors for short and long-term survival in patients selected for liver transplantation. Medicina (Kaunas) 2005; 41: 39-46.
82. Cholongitas E, Papatheodoridis GV, Vangeli M, Terreni N, Patch D, Burroughs AK. Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005; 22: 1079-89.
83. Cholongitas E, Marelli L, Shusang V et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006; 12: 1049-61.
84. Lalazar G, Mullhaupt B, Adar T, Goetze O, Mizrahi M, Safadi R, Zigmond E, Hemed N, Ilan Y. The non-invasive 13C-methacetin breath test accurately predicts long term survival in patients with chronic viral hepatitis and may serve aas an adjunctive tool to MELD: Results of a 395 patient clinical trial. Hepatology 50: 78A (Suppl 4), 2009.
85. Lalazar GAT, Mizrahi M, Zigmond E et al. The point of care 13C methacetin breath test accurately predicts long term prognosis in cirrhotic patients: a non-invasive online liver function test. Hepatology 2008; 48: 276A.
86. Lalazar GMB, Adar T, Goetze O et al. The point-of-care 13C methacetin breath test accurately assesses inflammation fibrosis and prognosis in patients with chronic viral hepatitis C and normal ALT: a non invasive liver function test. Hepatology 2009; 50: 272A.
87. Ichai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 2008; 14 (Suppl 2): S67-79.
88. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep 2007; 9: 66-73.
89. Lee WM, Seremba E. Etiologies of acute liver failure. Curr Opin Crit Care 2008; 14: 198-201.
90. Polson J. Assessment of prognosis in acute liver failure. Semin Liver Dis 2008; 28: 218-25.
91. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-26.
92. Bernal W, Auzinger G, Sizer E, Wendon J. Intensive care management of acute liver failure. Semin Liver Dis 2008; 28: 188-200.
93. Koffron A, Stein JA. Liver transplantation: indications, pretransplant evaluation, surgery, and posttransplant complications. Med Clin North Am 2008; 92: 861-88, ix.
94. Liou IW, Larson AM. Role of liver transplantation in acute liver failure. Semin Liver Dis 2008; 28: 201-9.
95. O'Grady JG. Postoperative issues and outcome for acute liver failure. Liver Transpl 2008; 14 (Suppl 2): S97-101.
96. Lalazar G, Adar T, Ilan Y. Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial. World J Gastroenterol 2009; 15: 966-72.
97. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006; 10: 207-17, vii.
98. Chang CY, Schiano TD. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007; 25: 1135-51.
99. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24: 287-97.
100. Gupta NK, Lewis JH. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008; 28: 1021-41.
101. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5-10.
102. Braun MPO, Margalit M, Lalazar G et al. Detection of nonalcoholic steatohepatitis and the extent of hepatic fibrosis with the innovative real-time BreathID test system in patients with NAFLD. Hepatology 2006; 44: 653A.
103. De Ridder RJ, Schoon EJ, Smulders JF, Van Hout GC, Stockbrugger RW, Koek GH. Review article: non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery. Aliment Pharmacol Ther 2007; 26 (Suppl 2): 195-201.
104. Rafiq N, Younossi ZM. Effects of weight loss on nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 427-33.
105. Lalazar GKA, Adar T, Mizrahi M, Zigmond E, Hemed N, Ilan Y. Assessment of hepatic mitochondrial beta-oxidation using the non-invasive 13C-octanoate breath test: a novel tool for assessment of liver function before and after bariatric surgery. Hepatolgogy 2008; 48: 215A.